Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

On the versatility of von Willebrand factor.

Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ.

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013046. doi: 10.4084/MJHID.2013.046. Print 2013.

2.

[Von Willebrand factor and ADAMTS13 balancing primary haemostasis].

Schneppenheim R, Budde U.

Hamostaseologie. 2011 Nov;31(4):275-80. doi: 10.5482/ha-1167. Epub 2011 Jul 20. Review. German.

PMID:
21792464
3.

von Willebrand factor: the old, the new and the unknown.

Lenting PJ, Casari C, Christophe OD, Denis CV.

J Thromb Haemost. 2012 Dec;10(12):2428-37. doi: 10.1111/jth.12008. Review.

5.

Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.

Budde U, Schneppenheim R.

Hamostaseologie. 2014;34(3):215-25. doi: 10.5482/HAMO-13-08-0045. Epub 2014 Jul 10. Review.

PMID:
25010251
6.

Von Willebrand factor: drug and drug target.

De Meyer SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K.

Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):9-20. Review.

PMID:
19275573
7.

Von Willebrand disease and Weibel-Palade bodies.

Wang JW, Eikenboom J.

Hamostaseologie. 2010 Aug;30(3):150-5. Review.

PMID:
20680229
8.

Molecular genetics of von Willebrand disease.

Mazurier C, Ribba AS, Gaucher C, Meyer D.

Ann Genet. 1998;41(1):34-43. Review.

PMID:
9599650
9.

Interaction of the von Willebrand factor with platelets and thrombosis.

Perutelli P, Mori PG.

Recenti Prog Med. 1997 Nov;88(11):526-9. Review.

PMID:
9401429
10.

von Willebrand factor: biological function and molecular defects.

Perutelli P, Biglino P, Mori PG.

Pediatr Hematol Oncol. 1997 Nov-Dec;14(6):499-512. Review.

PMID:
9383803
12.

[Diagnostic standards of von Willebrand disease].

Budde U, Drewke E, Will K, Schneppenheim R.

Hamostaseologie. 2004 Feb;24(1):12-26. Review. German.

PMID:
15029269
13.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
14.

von Willebrand factor and von Willebrand disease.

Ruggeri ZM, Zimmerman TS.

Blood. 1987 Oct;70(4):895-904. Review. Erratum in: Blood 1988 Mar;71(3):830.

15.

von Willebrand factor propeptide: biology and clinical utility.

Haberichter SL.

Blood. 2015 Oct 8;126(15):1753-61. doi: 10.1182/blood-2015-04-512731. Epub 2015 Jul 27.

16.

Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. Review.

PMID:
16959681
17.

Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.

Michiels JJ, van Vliet HH.

Acta Haematol. 2009;121(2-3):154-66. doi: 10.1159/000214856. Epub 2009 Jun 8. Review.

PMID:
19506362
18.
20.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Lillicrap D.

Hematology Am Soc Hematol Educ Program. 2013;2013:254-60. doi: 10.1182/asheducation-2013.1.254. Review.

PMID:
24319188

Supplemental Content

Support Center